Literature DB >> 29363833

Purine-related metabolites and their converting enzymes are altered in frontal, parietal and temporal cortex at early stages of Alzheimer's disease pathology.

Patricia Alonso-Andrés1, José Luis Albasanz1, Isidro Ferrer2,3,4,5, Mairena Martín1.   

Abstract

Adenosine, hypoxanthine, xanthine, guanosine and inosine levels were assessed by HPLC, and the activity of related enzymes 5'-nucleotidase (5'-NT), adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) measured in frontal (FC), parietal (PC) and temporal (TC) cortices at different stages of disease progression in Alzheimer's disease (AD) and in age-matched controls. Significantly decreased levels of adenosine, guanosine, hypoxanthine and xanthine, and apparently less inosine, are found in FC from the early stages of AD; PC and TC show an opposing pattern, as adenosine, guanosine and inosine are significantly increased at least at determinate stages of AD whereas hypoxanthine and xanthine levels remain unaltered. 5'-NT is reduced in membranes and cytosol in FC mainly at early stages but not in PC, and only at advanced stages in cytosol in TC. ADA activity is decreased in AD when considered as a whole but increased at early stages in TC. Finally, PNP activity is increased only in TC at early stages. Purine metabolism alterations occur at early stages of AD independently of neurofibrillary tangles and β-amyloid plaques. Alterations are stage dependent and region dependent, the latter showing opposite patterns in FC compared with PC and TC. Adenosine is the most affected of the assessed purines.
© 2018 International Society of Neuropathology.

Entities:  

Keywords:  Alzheimer's disease; adenosine; cerebral cortex; purine metabolism

Mesh:

Substances:

Year:  2018        PMID: 29363833     DOI: 10.1111/bpa.12592

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  25 in total

1.  Explaining a series of models by propagating Shapley values.

Authors:  Hugh Chen; Scott M Lundberg; Su-In Lee
Journal:  Nat Commun       Date:  2022-08-03       Impact factor: 17.694

Review 2.  A2A Adenosine Receptor Antagonists in Neurodegenerative Diseases.

Authors:  Stefania Merighi; Pier A Borea; Katia Varani; Fabrizio Vincenzi; Kenneth A Jacobson; Stefania Gessi
Journal:  Curr Med Chem       Date:  2022       Impact factor: 4.740

Review 3.  Expanding the clinical relevance of the 5'-nucleotidase cN-II/NT5C2.

Authors:  Lars Petter Jordheim
Journal:  Purinergic Signal       Date:  2018-10-25       Impact factor: 3.765

Review 4.  Metabolic Aspects of Adenosine Functions in the Brain.

Authors:  Mercedes Garcia-Gil; Marcella Camici; Simone Allegrini; Rossana Pesi; Maria Grazia Tozzi
Journal:  Front Pharmacol       Date:  2021-05-14       Impact factor: 5.810

Review 5.  Glial Purinergic Signaling in Neurodegeneration.

Authors:  Marie J Pietrowski; Amr Ahmed Gabr; Stanislav Kozlov; David Blum; Annett Halle; Kevin Carvalho
Journal:  Front Neurol       Date:  2021-05-14       Impact factor: 4.003

Review 6.  The Adenosinergic Signaling: A Complex but Promising Therapeutic Target for Alzheimer's Disease.

Authors:  Lucrezia Cellai; Kevin Carvalho; Emilie Faivre; Aude Deleau; Didier Vieau; Luc Buée; David Blum; Céline Mériaux; Victoria Gomez-Murcia
Journal:  Front Neurosci       Date:  2018-08-03       Impact factor: 4.677

Review 7.  Redox signaling and Alzheimer's disease: from pathomechanism insights to biomarker discovery and therapy strategy.

Authors:  Yuan-Yuan Chen; Min-Chang Wang; Yan-Ni Wang; He-He Hu; Qing-Quan Liu; Hai-Jing Liu; Ying-Yong Zhao
Journal:  Biomark Res       Date:  2020-09-11

8.  Modified Huang-Lian-Jie-Du Decoction Ameliorates Aβ Synaptotoxicity in a Murine Model of Alzheimer's Disease.

Authors:  Yan Liu; Ting Du; Wenlong Zhang; Weiye Lu; Zhichao Peng; Shuqiong Huang; Xiangdong Sun; Xiaoqin Zhu; Chaojun Chen; Linchao Qian; Lei Wen; Pingyi Xu; Yunlong Zhang
Journal:  Oxid Med Cell Longev       Date:  2019-11-03       Impact factor: 6.543

9.  Iron dyshomeostasis, lipid peroxidation and perturbed expression of cystine/glutamate antiporter in Alzheimer's disease: Evidence of ferroptosis.

Authors:  Azhaar Ashraf; Jérôme Jeandriens; Harold G Parkes; Po-Wah So
Journal:  Redox Biol       Date:  2020-03-05       Impact factor: 11.799

10.  Equilibrative nucleoside transporter 1 inhibition rescues energy dysfunction and pathology in a model of tauopathy.

Authors:  Ching-Pang Chang; Ya-Gin Chang; Pei-Yun Chuang; Thi Ngoc Anh Nguyen; Kuo-Chen Wu; Fang-Yi Chou; Sin-Jhong Cheng; Hui-Mei Chen; Lee-Way Jin; Kevin Carvalho; Vincent Huin; Luc Buée; Yung-Feng Liao; Chun-Jung Lin; David Blum; Yijuang Chern
Journal:  Acta Neuropathol Commun       Date:  2021-06-22       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.